Press Releases Choose Year All Items 2025 (2) 2024 (3) 2023 (4) 2022 (1) Search Press Releases Found 10 Results Sep182025 Cullgen Completes Enrollment in Phase 1 Trial of its Novel Non-Opioid Pain Product Candidate CG001419 Jan232025 Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain Nov142024 PULMATRIX AND CULLGEN ANNOUNCE PROPOSED MERGER Oct92024 CULLGEN ANNOUNCES CHINESE NMPA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CG009301, A HIGHLY SELECTIVE GSPT1 DEGRADER Jan172024 CULLGEN ANNOUNCES ADDITIONS TO BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD Oct162023 CULLGEN AND ASTELLAS HONORED WITH 2023 LES DEALS OF DISTINCTION AWARD Jul272023 Cullgen Announces First-In-Human Dose in Phase I/II Trial of CG001419, a First-in-Class TRK Protein Degrader for Treatment of Cancer Patients Jun152023 Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders May92023 Cullgen Raises $40 Million in New Financing Led by AstraZeneca-CICC Fund Aug102022 Cullgen Announces Chinese NMPA Allowance of Investigational New Drug Application of TRK Degrader to Begin Clinical Trials View the Pulmatrix Press Releases
